Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mr Toda Warns Consumers against Counterfeit Drugs Sold Via Internet
March 16, 2009
- Shasun to Enhance Its Presence in Japan via Its Subsidiary in Tokyo
March 16, 2009
- Guidance on Biosimilars Issued by Korosho
March 16, 2009
- Chuikyo Subcommittee Discusses Pros and Cons of "Generics Coefficient"
March 16, 2009
- Opposition Disagrees with Reappointment of Prof. Maeda as Chuikyo Member
March 9, 2009
- Data from Ranbaxy Plant Are Falsified: FDA
March 9, 2009
- Chugai's Avastin Should Be Indicated for Stomach Cancer
March 9, 2009
- Tasigna Recommended in 2nd-Line Therapy: Prof. Ohyashiki
March 9, 2009
- Constipation Should Be Treated by Physicians: Dr Hongo
March 9, 2009
- Clinical Trial Operations Streamlined at Pfizer Japan
March 9, 2009
- Eisai to Create Independent Units in 6 Fields to Accelerate Development
March 9, 2009
- Increased Dose of Amlodipine Approved
March 9, 2009
- Daiichi Sankyo Pursues Optimal Promotion Mixes
March 9, 2009
- Astellas to Diversify Development Programs
March 9, 2009
- Teva-Kowa Aims at Becoming a Leading GE Maker in Japan in 2015
March 9, 2009
- R&D NEWS IN BRIEF
March 9, 2009
- Shire Enters Japanese Market by Opening Office in Tokyo
March 9, 2009
- RDKK Maintains Higher-Than-Industry-Average Growth Rate
March 9, 2009
- Abbott Japan Acquires Rights to Market Amitiza in Japan
March 9, 2009
- Review Period Reduced, but Submittal Lag Still Long: ACCJ Report
March 9, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…